Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Envoy Medical (COCH) EBITDA Margin (2022 - 2025)

Envoy Medical's EBITDA Margin history spans 4 years, with the latest figure at 15435.71% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 479107.0% year-over-year to 15435.71%; the TTM value through Sep 2025 reached 10440.38%, down 285873.0%, while the annual FY2024 figure was 8558.22%, 91171.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 15435.71% at Envoy Medical, down from 7297.44% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1952.5% in Q3 2023 and bottomed at 57405.0% in Q4 2022.
  • The 4-year median for EBITDA Margin is 10644.64% (2024), against an average of 13267.33%.
  • The largest annual shift saw EBITDA Margin surged 5225026bps in 2023 before it tumbled -1259714bps in 2024.
  • A 4-year view of EBITDA Margin shows it stood at 57405.0% in 2022, then skyrocketed by 91bps to 5154.74% in 2023, then crashed by -110bps to 10830.95% in 2024, then plummeted by -43bps to 15435.71% in 2025.
  • Per Business Quant, the three most recent readings for COCH's EBITDA Margin are 15435.71% (Q3 2025), 7297.44% (Q2 2025), and 10852.17% (Q1 2025).